Cutler Group’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-1,600
Closed -$2K – 4389
2022
Q3
$2K Buy
+1,600
New +$91.3K ﹤0.01% 4143
2021
Q3
– Sell
-8,900
Closed -$182K – 5701
2021
Q2
$182K Sell
8,900
-27,500
-76% -$2.19M 0.01% 1407
2021
Q1
$94K Buy
+36,400
New +$3.46M ﹤0.01% 1820

Other funds holding BEAM

Cutler Group's BEAM Position: Q1 2024 in Review

Cutler Group sold out of Beam Therapeutics (BEAM) in Q1 2024, closing a stake of 50 shares — an estimated $1K sold.

Cutler Group first reported a position in BEAM in Q4 2020 and held it in 7 quarters. The position peaked at $204K in Q4 2020. 221 funds tracked by Wall St. Rank hold BEAM as of Q1 2024.

  • Cutler Group reported no remaining Beam Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 50 Beam Therapeutics shares in Q1 2024, an estimated $1K.
  • Cutler Group first reported a position in Beam Therapeutics in Q4 2020 and held it in 7 quarters.
  • Cutler Group's Beam Therapeutics position peaked at $204K in Q4 2020.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.